TRIAMCINOLONE ACETONIDE | N208845 | PACIRA PHARMACEUTICALS INC
| Trial | Phase | Status | Sponsor | Enrollment | Dates |
|---|---|---|---|---|---|
| Phase 4 | Recruiting | Wake Forest University Health Sciences | 250 | 2018-04-30 → 2027-03 | |
| Phase 3 | Recruiting | University of Washington | 120 | 2013-12 → 2026-07 | |
| Phase 3 | Completed | Shahid Beheshti University of Medical Sciences | — | 2001-06 → 2003-06 | |
| Early Phase 1 | Completed | National Eye Institute (NEI) | 100 | 2006-07 → 2009-07 | |
| Phase 3 | Completed | Novartis Pharmaceuticals | 226 | 2010-03 → 2011-10 | |
| Phase 2 | Completed | Universidade Federal de Goias | 13 | 2008-03 → 2008-10 | |
| N/A | Completed | Yonsei University | 111 | 2012-07 → 2013-04 | |
| N/A | Completed | Taipei Veterans General Hospital, Taiwan | 52 | 2013-04 → 2014-06 | |
| Phase 3 | Completed | Carbylan Therapeutics, Inc. | 510 | 2014-01 → 2016-06 | |
| Phase 3 | Completed | Novartis Pharmaceuticals | 111 | 2005-09 |
Source: ClinicalTrials.gov. Trials matched by ingredient name.
Lowest Price
$420.95
Highest Price
$615.07
FSS NDCs
1
Big4 NDCs
1
| Description | Price | Type | Vendor | Contract End |
|---|---|---|---|---|
| 65250-0003-01ZILRETTA 32MG/VIL INJ,SUSP,SA | $615.07 | FSS | Pacira Therapeutics, Inc. | 08/31/2029 |
| 65250-0003-01ZILRETTA 32MG/VIL INJ,SUSP,SA | $420.95 | Big4 | Pacira Therapeutics, Inc. | 08/31/2029 |
Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.
Total Spending
$1.9M
Total Claims
2,092
Beneficiaries
1,377
Avg Cost/Unit
$644.02
Spending Trend
Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.
Total Spending
$64.8M
Total Claims
90,238
Beneficiaries
51,173
ASP Price
$17.65
Spending Trend
HCPCS: J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg
Source: CMS Medicare Part B Spending by Drug (2024). Shows physician-administered drug costs.
12 active API suppliers hold Drug Master Files for this ingredient.
Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.
| Date | Submission | Document |
|---|---|---|
| Dec 4, 2024 | SUPPL -21 | View Letter (PDF) |
| Sep 6, 2024 | SUPPL -19 | View Letter (PDF) |
| Dec 3, 2020 | SUPPL -11 | View Letter (PDF) |
| Dec 26, 2019 | SUPPL -7 | View Letter (PDF) |
| Oct 12, 2017 | ORIG -1 | View Letter (PDF) |
Source: Drugs@FDA application documents.